Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells.
Saved in:
| Title: | Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells. |
|---|---|
| Authors: | Jones D; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia., Whitehead CA; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia., Dinevska M; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia., Widodo SS; Department of Microbiology and Immunology, School of Biomedical Sciences, The University of Melbourne, Parkville, VIC, 3010, Australia., Furst LM; Department of Microbiology and Immunology, School of Biomedical Sciences, The University of Melbourne, Parkville, VIC, 3010, Australia., Morokoff AP; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.; Department of Neurosurgery, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia., Kaye AH; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.; Hadassah University Medical Centre, 91120, Jerusalem, Israel., Drummond KJ; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.; Department of Neurosurgery, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia., Mantamadiotis T; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.; Department of Microbiology and Immunology, School of Biomedical Sciences, The University of Melbourne, Parkville, VIC, 3010, Australia., Stylli SS; Level 5, Clinical Sciences Building, Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia. stanley.stylli@mh.org.au.; Department of Neurosurgery, The Royal Melbourne Hospital, Parkville, VIC, 3050, Australia. stanley.stylli@mh.org.au. |
| Source: | Molecular and cellular biochemistry [Mol Cell Biochem] 2023 Jun; Vol. 478 (6), pp. 1251-1267. Date of Electronic Publication: 2022 Oct 27. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Country of Publication: Netherlands NLM ID: 0364456 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-4919 (Electronic) Linking ISSN: 03008177 NLM ISO Abbreviation: Mol Cell Biochem Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1573-4919 |
|---|---|
| DOI: | 10.1007/s11010-022-04584-0 |
